Journal
ONCOGENE
Volume 38, Issue 44, Pages 6970-6984Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41388-019-0932-1
Keywords
-
Funding
- National Natural Science Foundation of China [81788101, 81530080, 81601366]
- CAMS Initiative for Innovative Medicine [2016-I2M-1-007]
Ask authors/readers for more resources
Clinical applications of antiangiogenic agents profoundly affect tumor cell behaviors via the resultant hypoxia. To date, how the hypoxia regulates tumor cells remains unclear. Here, we show that hypoxia promotes the growth of human breast tumorigenic cells that repopulate tumors [tumor-repopulating cells (TRCs)] in vitro and in vivo. This stimulating effect is ascribed to hypoxia-induced reactive oxygen species (ROS) that activates Akt and NF-kappa B, dependent on the attenuated tricarboxylic acid (TCA) cycle. We find that fumarate is accumulated in the TCA cycle of hypoxic TRCs, leading to glutathione succination, NADPH/NADP(+) decrease, and an increase in ROS levels. Mechanistically, hypoxia-increased HIF-1 alpha transcriptionally downregulates the expression of mitochondrial phosphoenolpyruvate carboxykinase (PCK2), leading to TCA cycle attenuation and fumarate accumulation. These findings reveal that hypoxia-reprogrammed TCA cycle promotes human breast TRCs growth via a HIF-1 alpha-downregulated PCK2 pathway, implying a need for a combination of an antiangiogenic therapy with an antioxidant modulator.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available